Tag Archives: John Newman
Canaccord Genuity Maintains a Buy Rating on ImmunoGen (IMGN)
In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on ImmunoGen (IMGN – Research Report), with a price target of $12.00. The company’s shares closed last Wednesday at $4.08. According to TipRanks.com, Newman is a
Canaccord Genuity Maintains Their Buy Rating on Bluebird Bio (BLUE)
Canaccord Genuity analyst John Newman maintained a Buy rating on Bluebird Bio (BLUE – Research Report) yesterday and set a price target of $118.00. The company’s shares closed last Tuesday at $60.86. According to TipRanks.com, Newman is a 5-star analyst
Canaccord Genuity Sticks to Their Buy Rating for Aileron Therapeutics (ALRN)
In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Aileron Therapeutics (ALRN – Research Report), with a price target of $5.00. The company’s shares closed last Tuesday at $0.63. According to TipRanks.com, Newman is
Canaccord Genuity Thinks Sesen Bio’s Stock is Going to Recover
Canaccord Genuity analyst John Newman maintained a Buy rating on Sesen Bio (SESN – Research Report) yesterday and set a price target of $5.00. The company’s shares closed last Tuesday at $0.69, close to its 52-week low of $0.37. According
Canaccord Genuity Keeps a Buy Rating on Seres Therapeutics (MCRB)
In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Seres Therapeutics (MCRB – Research Report), with a price target of $11.00. The company’s shares closed last Thursday at $4.27. According to TipRanks.com, Newman is
Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN), ACADIA Pharmaceuticals (NASDAQ: ACAD) and Premier (NASDAQ: PINC)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regeneron (REGN – Research Report), ACADIA Pharmaceuticals (ACAD – Research Report) and Premier (PINC – Research Report) with bullish sentiments. Regeneron (REGN)
